AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Purple Biotech to sell 2.7M American Depositary Shares, warrants
ByAinvest
Saturday, Aug 30, 2025 4:29 am ET1min read
Purple Biotech has filed to sell 2.7 million American Depositary Shares and warrants. H.C. Wainwright & Co. is acting as the manager for the sale. The move aims to raise funds for the company's operations and growth plans.
Purple Biotech (NASDAQ/TASE: PPBT), a clinical-stage biotechnology company focused on developing first-in-class therapies for tumor immune evasion and drug resistance, has announced its intention to sell 2.7 million American Depositary Shares (ADS) and warrants. The move is aimed at raising funds to support the company's ongoing operations and growth plans. H.C. Wainwright & Co. is acting as the manager for the sale.The company's CEO, Gil Efron, will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 27th Annual Global Investment Conference, scheduled for September 8-10, 2025, in New York City. This event provides an opportunity for investors to gain insights into Purple Biotech's pipeline and strategic plans. The fireside chat is set for September 10, 2025, at 11:30 AM ET.
Purple Biotech's pipeline includes CAPTN-3, CM24, and NT219. CAPTN-3 is a preclinical platform of conditionally activated tri-specific antibodies that engage both T cells and NK cells to induce a strong, localized immune response within the tumor microenvironment. CM24 is a humanized monoclonal antibody that blocks CEACAM1, supporting tumor immune evasion and survival through multiple pathways. NT219 is a dual inhibitor that targets IRS1/2 and STAT3, with demonstrated anti-tumor activity in combination with cetuximab in second-line patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
The sale of ADS and warrants is a strategic move for Purple Biotech to secure additional capital for its research and development efforts, as well as to expand its clinical trials and commercialization plans. The company's headquarters are located in Rehovot, Israel.
References:
[1] https://www.stocktitan.net/news/PPBT/purple-biotech-to-participate-in-the-h-c-wainwright-27th-annual-5bm0ey4icnik.html
[2] https://www.ainvest.com/news/realpha-strategic-momentum-ai-driven-real-estate-disruption-investor-access-wainwright-2508/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet